Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer

od Casneuf, Tineke, Axel, Amy E, King, Peter, Alvarez, John D, Werbeck, Jillian L, Verhulst, Tinne, Verstraeten, Karin, Hall, Brett M, Sasser, A Kate
Wydane w Breast Cancer (Dove Med Press) (2016)

Prognostic significance of interleukin-6 single nucleotide polymorphism genotypes in neuroblastoma: rs1800795 (promoter) and rs8192284 (receptor)

od Lagmay, Joanne P., London, Wendy B., Gross, Thomas G., Termuhlen, Amanda, Sullivan, Nicholas, Axel, Amy, Mundy, Bethany, Ranalli, Mark, Canner, Jason, McGrady, Patrick, Hall, Brett
Wydane 2009

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma

od Casneuf, Tineke, Xu, Xu Steven, Adams, Homer C., Axel, Amy E., Chiu, Christopher, Khan, Imran, Ahmadi, Tahamtan, Yan, Xiaoyu, Lonial, Sagar, Plesner, Torben, Lokhorst, Henk M., van de Donk, Niels W. C. J., Clemens, Pamela L., Sasser, A. Kate
Wydane w Blood Adv (2017)

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

od Usmani, Saad Z., Weiss, Brendan M., Plesner, Torben, Bahlis, Nizar J., Belch, Andrew, Lonial, Sagar, Lokhorst, Henk M., Voorhees, Peter M., Richardson, Paul G., Chari, Ajai, Sasser, A. Kate, Axel, Amy, Feng, Huaibao, Uhlar, Clarissa M., Wang, Jianping, Khan, Imran, Ahmadi, Tahamtan, Nahi, Hareth
Wydane w Blood (2016)

Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus

od Cole, Suzanne, Walsh, Alice, Yin, Xuefeng, Wechalekar, Mihir D., Smith, Malcolm D., Proudman, Susanna M., Veale, Douglas J., Fearon, Ursula, Pitzalis, Costantino, Humby, Frances, Bombardieri, Michele, Axel, Amy, Adams, Homer, Chiu, Christopher, Sharp, Michael, Alvarez, John, Anderson, Ian, Madakamutil, Loui, Nagpal, Sunil, Guo, Yanxia
Wydane w Arthritis Res Ther (2018)

Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma

od Verkleij, Christie P. M., Broekmans, Marloes E. C., van Duin, Mark, Frerichs, Kristine A., Kuiper, Rowan, de Jonge, A. Vera, Kaiser, Martin, Morgan, Gareth, Axel, Amy, Boominathan, Rengasamy, Sendecki, Jocelyn, Wong, Amy, Verona, Raluca I., Sonneveld, Pieter, Zweegman, Sonja, Adams, Homer C., Mutis, Tuna, van de Donk, Niels W. C. J.
Wydane w Blood Adv (2021)

Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab

od Casneuf, Tineke, Adams, Homer C., van de Donk, Niels W.C.J., Abraham, Yann, Bald, Jaime, Vanhoof, Greet, Van der Borght, Koen, Smets, Tina, Foulk, Brad, Nielsen, Karl C., Rusbuldt, Joshua, Axel, Amy, Lysaght, Andrew, Ceulemans, Hugo, Stevenaert, Frederik, Usmani, Saad Z., Plesner, Torben, Avet-Loiseau, Herve, Nijhof, Inger, Mutis, Tuna, Schecter, Jordan M., Chiu, Christopher, Bahlis, Nizar J.
Wydane w Leukemia (2020)